Free Trial
→ Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Buy BEAM Stock  Free BEAM Stock Alerts

Beam Therapeutics (BEAM) Financials

Beam Therapeutics logo
$17.75 +0.09 (+0.51%)
As of 05/20/2025 04:00 PM Eastern
Compare
Annual Income Statements for Beam Therapeutics

Annual Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -377 -133 -289 -371 -196 -91
Consolidated Net Income / (Loss)		 -377 -133 -289 -371 -195 -78
Net Income / (Loss) Continuing Operations		 -377 -133 -289 -371 -195 -78
Total Pre-Tax Income 		-377 -131 -260 -371 -195 -78
Total Operating Income		 -416 -176 -338 -392 -133 -75
Total Gross Profit		 64 378 61 52 0.02 0.02
Total Revenue		 64 378 61 52 0.02 0.02
Operating Revenue		 64 378 61 52 0.02 0.02
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 479 554 399 444 133 75
Selling, General & Admin Expense		 112 117 88 57 30 21
Research & Development Expense		 368 437 312 387 103 55
Total Other Income / (Expense), net		 39 45 78 22 -62 -3.17
Interest Expense		 -49 -47 -15 0.01 -1.05 -2.23
Other Income / (Expense), net		 -10 -1.35 63 22 -63 -5.40
Income Tax Expense		 0.04 1.37 3.41 0.00 0.00 -
Other Gains / (Losses), net		 0.00 0.00 -26 0.00 0.00 -
Basic Earnings per Share		 ($4.58) ($1.72) ($4.13) ($5.77) ($4.19) ($14.05)
Weighted Average Basic Shares Outstanding		 82.31M 77.15M 70.02M 64.23M 46.73M 6.48M
Diluted Earnings per Share		 ($4.58) ($1.72) ($4.13) ($5.77) ($4.19) ($14.05)
Weighted Average Diluted Shares Outstanding		 82.31M 77.15M 70.02M 64.23M 46.73M 6.48M
Weighted Average Basic & Diluted Shares Outstanding		 83.69M 81.66M 72.40M 68.73M 46.73M 6.48M

Quarterly Income Statements for Beam Therapeutics

This table shows Beam Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -109 -90 -97 -91 -99 143 -96 -83 -96 -38 -110
Consolidated Net Income / (Loss)		 -109 -90 -97 -91 -99 143 -96 -83 -96 -38 -110
Net Income / (Loss) Continuing Operations		 -109 -90 -97 -91 -99 143 -96 -83 -96 -38 -110
Total Pre-Tax Income 		-109 -189 -97 -91 0.00 48 -96 -83 0.00 -37 -82
Total Operating Income		 -119 -100 -107 -105 -104 133 -108 -102 -99 -89 -91
Total Gross Profit		 7.47 30 14 12 7.41 316 17 20 24 20 16
Total Revenue		 7.47 30 14 12 7.41 316 17 20 24 20 16
Operating Revenue		 7.47 30 14 12 7.41 316 17 20 24 20 16
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 127 130 121 117 112 183 125 122 123 109 107
Selling, General & Admin Expense		 28 29 27 30 27 43 25 25 23 23 22
Research & Development Expense		 99 101 94 87 85 140 100 98 100 86 85
Other Special Charges / (Income)		 0.03 - - - - - - - - - -
Total Other Income / (Expense), net		 10 9.68 9.84 14 5.46 11 12 19 2.47 52 9.64
Interest Expense		 -9.86 -11 -12 -14 -12 -12 -13 -12 -9.96 -7.61 -4.98
Other Income / (Expense), net		 0.18 -1.25 -2.29 -0.31 -6.39 -0.76 -0.52 7.42 -7.49 44 4.66
Basic Earnings per Share		 ($1.24) ($1.09) ($1.17) ($1.11) ($1.21) $1.91 ($1.22) ($1.08) ($1.33) ($0.54) ($1.56)
Weighted Average Basic Shares Outstanding		 87.98M 82.31M 82.41M 82.31M 81.70M 77.15M 79.02M 76.34M 72.27M 70.02M 70.34M
Diluted Earnings per Share		 ($1.24) ($1.09) ($1.17) ($1.11) ($1.21) $1.91 ($1.22) ($1.08) ($1.33) ($0.54) ($1.56)
Weighted Average Diluted Shares Outstanding		 87.98M 82.31M 82.41M 82.31M 81.70M 77.15M 79.02M 76.34M 72.27M 70.02M 70.34M
Weighted Average Basic & Diluted Shares Outstanding		 100.56M 83.69M 82.81M 82.42M 82.31M 81.66M 81.50M 79.20M 76.22M 72.40M 70.47M

Annual Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 -155 199 -327 396 126 -97
Net Cash From Operating Activities		 -347 -149 23 -66 -96 -72
Net Cash From Continuing Operating Activities		 -347 -149 23 -66 -96 -72
Net Income / (Loss) Continuing Operations		 -377 -133 -289 -371 -195 -78
Consolidated Net Income / (Loss)		 -377 -133 -289 -371 -195 -78
Depreciation Expense		 22 20 14 7.45 4.74 3.50
Amortization Expense		 -13 -20 -0.98 -0.08 0.12 -0.92
Non-Cash Adjustments To Reconcile Net Income		 120 99 378 -109 92 12
Changes in Operating Assets and Liabilities, net		 -99 -116 -80 406 2.20 -8.17
Net Cash From Investing Activities		 185 72 -461 -294 -100 -67
Net Cash From Continuing Investing Activities		 185 72 -461 -294 -99 -66
Purchase of Property, Plant & Equipment		 -8.95 -34 -49 -47 -16 -13
Purchase of Investments		 -486 -984 -1,617 -777 -282 -130
Divestitures		 0.00 0.00 0.00 0.62 0.00 0.00
Sale and/or Maturity of Investments		 680 1,090 1,205 529 199 76
Net Cash From Financing Activities		 7.74 276 112 756 322 41
Net Cash From Continuing Financing Activities		 7.74 276 112 756 322 41
Repayment of Debt		 -0.49 -2.25 -2.29 - -1.57 -0.46
Repurchase of Common Equity		 0.00 -0.63 -0.19 -8.82 -2.06 -2.52
Issuance of Common Equity		 2.62 273 111 757 320 0.00
Other Financing Activities, net		 5.60 6.13 2.73 7.51 3.16 0.19
Cash Interest Paid		 0.03 0.16 0.38 0.57 0.56 0.19

Quarterly Cash Flow Statements for Beam Therapeutics

This table details how cash moves in and out of Beam Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 244 53 -62 4.62 -150 267 -63 -19 14 76 -109
Net Cash From Operating Activities		 -104 -76 -88 -83 -100 135 -90 -85 -110 -69 -74
Net Cash From Continuing Operating Activities		 -104 -76 -88 -83 -100 135 -90 -85 -110 -69 -74
Net Income / (Loss) Continuing Operations		 -109 -90 -97 -91 -99 143 -96 -83 -96 -38 -110
Consolidated Net Income / (Loss)		 -109 -90 -97 -91 -99 143 -96 -83 -96 -38 -110
Depreciation Expense		 5.53 5.44 5.48 5.58 5.43 5.36 5.19 4.82 4.65 3.94 3.47
Amortization Expense		 -3.85 5.03 -5.62 -5.93 -6.58 2.17 -7.88 -7.57 -6.93 3.33 -3.22
Non-Cash Adjustments To Reconcile Net Income		 29 21 31 33 35 7.81 35 26 31 4.11 32
Changes in Operating Assets and Liabilities, net		 -25 -17 -22 -25 -35 -23 -26 -25 -42 -42 2.85
Net Cash From Investing Activities		 -125 126 25 87 -53 98 -10 -41 25 113 -36
Net Cash From Continuing Investing Activities		 -125 126 25 87 -53 98 -10 -41 25 113 -36
Purchase of Property, Plant & Equipment		 -3.07 -2.97 -1.58 -1.96 -2.44 -3.59 -7.95 -16 -6.02 -8.26 -12
Purchase of Investments		 -339 - -157 -134 -195 -53 -274 -391 -267 -238 -358
Sale and/or Maturity of Investments		 217 129 183 224 144 155 271 366 298 360 334
Net Cash From Financing Activities		 473 3.44 1.26 0.13 2.90 34 37 108 98 32 1.56
Net Cash From Continuing Financing Activities		 473 3.44 1.26 0.13 2.90 34 37 108 98 32 1.56
Repayment of Debt		 0.00 - -0.20 -0.11 -0.18 -0.63 -0.40 -0.62 -0.60 -0.59 -0.58
Repurchase of Common Equity		 0.00 - - - 0.00 - -0.38 -0.19 -0.06 -0.05 -0.03
Issuance of Common Equity		 473 -0.00 1.22 - 1.40 34 36 108 96 32 1.66
Other Financing Activities, net		 0.72 3.45 0.24 0.24 1.68 0.75 1.29 0.70 3.39 0.76 0.50
Cash Interest Paid		 0.00 - 0.01 0.01 0.01 0.02 0.03 0.05 0.06 0.08 0.09

Annual Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 1,104 1,460 1,342 1,474 452 156
Total Current Assets		 878 1,211 1,093 1,273 308 95
Cash & Equivalents		 282 436 233 560 162 37
Short-Term Investments		 569 754 845 406 138 55
Prepaid Expenses		 27 21 15 7.36 8.65 2.70
Plant, Property, & Equipment, net		 111 125 116 84 39 24
Total Noncurrent Assets		 114 124 133 117 105 37
Other Noncurrent Operating Assets		 114 124 133 117 105 37
Total Liabilities & Shareholders' Equity		 1,104 1,460 1,342 1,474 452 156
Total Liabilities		 370 478 608 648 206 55
Total Current Liabilities		 182 206 224 213 102 29
Accounts Payable		 3.87 1.62 9.03 7.47 6.31 7.85
Accrued Expenses		 47 112 50 68 18 7.85
Current Deferred Revenue		 109 69 136 86 0.02 -
Other Current Liabilities		 22 24 29 52 78 13
Total Noncurrent Liabilities		 188 273 385 434 104 26
Noncurrent Deferred Revenue		 33 110 202 262 0.39 -
Other Noncurrent Operating Liabilities		 155 163 182 172 103 22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 734 981 733 827 246 -201
Total Preferred & Common Equity		 734 981 733 827 246 -201
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 734 981 733 827 246 -201
Common Stock		 2,299 2,171 1,793 1,595 643 1.92
Retained Earnings		 -1,567 -1,190 -1,057 -768 -398 -203
Accumulated Other Comprehensive Income / (Loss)		 0.68 0.60 -2.43 -0.05 -0.01 0.02

Quarterly Balance Sheets for Beam Therapeutics

This table presents Beam Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,467 1,171 1,261 1,360 1,291 1,354 1,332 1,350
Total Current Assets		 1,248 946 1,029 1,122 1,040 1,095 1,083 1,109
Cash & Equivalents		 528 230 293 288 169 226 250 157
Short-Term Investments		 692 696 715 807 846 847 810 938
Prepaid Expenses		 28 20 21 27 24 22 24 14
Plant, Property, & Equipment, net		 110 114 117 121 128 128 122 111
Total Noncurrent Assets		 110 112 114 117 123 131 127 130
Other Noncurrent Operating Assets		 110 112 114 117 123 131 127 130
Total Liabilities & Shareholders' Equity		 1,467 1,171 1,261 1,360 1,291 1,354 1,332 1,350
Total Liabilities		 344 380 407 446 512 542 571 636
Total Current Liabilities		 142 166 177 187 220 210 220 239
Accounts Payable		 7.70 3.81 4.43 2.79 3.18 6.89 14 7.02
Accrued Expenses		 30 52 67 86 42 38 38 39
Current Deferred Revenue		 85 89 85 72 153 139 143 160
Other Current Liabilities		 18 21 21 26 22 26 25 33
Total Noncurrent Liabilities		 202 214 230 259 291 333 351 397
Noncurrent Deferred Revenue		 49 58 75 100 125 156 172 198
Other Noncurrent Operating Liabilities		 153 156 154 160 167 177 179 199
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,123 791 854 913 779 812 762 714
Total Preferred & Common Equity		 1,123 791 854 913 779 812 762 714
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,123 791 854 913 779 812 762 714
Common Stock		 2,799 2,266 2,235 2,203 2,114 2,050 1,916 1,738
Retained Earnings		 -1,676 -1,476 -1,380 -1,289 -1,333 -1,237 -1,154 -1,019
Accumulated Other Comprehensive Income / (Loss)		 0.16 1.76 -1.11 -0.92 -2.02 -2.02 -0.77 -4.67

Annual Metrics And Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 -83.18% 520.01% 17.51% 215,916.67% 33.33% 0.00%
EBITDA Growth		 -134.19% 32.12% 27.79% -90.39% -144.69% 0.00%
EBIT Growth		 -139.43% 35.44% 25.67% -89.44% -142.87% 0.00%
NOPAT Growth		 -135.47% 47.86% 13.76% -195.62% -76.65% 0.00%
Net Income Growth		 -184.28% 54.16% 22.00% -90.47% -148.44% 0.00%
EPS Growth		 -166.28% 58.35% 28.42% -37.71% 70.18% 0.00%
Operating Cash Flow Growth		 -132.75% -762.29% 133.99% 30.78% -32.97% 0.00%
Free Cash Flow Firm Growth		 -47.22% -732.64% 83.58% -650.28% 0.00% 0.00%
Invested Capital Growth		 43.80% 39.49% -148.12% -156.72% -500.58% 0.00%
Revenue Q/Q Growth		 -81.83% 363.14% -33.75% 6,538.16% 0.00% 0.00%
EBITDA Q/Q Growth		 -112.68% 51.06% 8.54% 8.09% -53.80% 0.00%
EBIT Q/Q Growth		 -121.29% 49.89% 6.71% 7.66% -52.47% 0.00%
NOPAT Q/Q Growth		 -127.49% 55.69% -8.15% -6.13% -12.19% 0.00%
Net Income Q/Q Growth		 -162.37% 57.75% 8.36% 7.66% -53.25% 0.00%
EPS Q/Q Growth		 -189.87% 58.75% 5.28% 14.90% 39.36% 0.00%
Operating Cash Flow Q/Q Growth		 -155.69% 57.79% -75.92% 28.28% -7.28% 0.00%
Free Cash Flow Firm Q/Q Growth		 -66.23% 38.53% -154.84% -21.08% 0.00% 0.00%
Invested Capital Q/Q Growth		 12.83% 11.83% 9.32% -33.40% -2,417.92% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -656.46% -47.14% -430.58% -700.67% -794,958.33% -433,172.22%
Operating Margin		 -654.25% -46.73% -555.61% -757.01% -553,166.67% -417,522.22%
EBIT Margin		 -670.36% -47.08% -452.19% -714.89% -815,179.17% -447,522.22%
Profit (Net Income) Margin		 -593.13% -35.09% -474.54% -714.91% -810,800.00% -435,144.44%
Tax Burden Percent		 100.01% 101.04% 111.11% 100.00% 100.00% 100.00%
Interest Burden Percent		 88.47% 73.75% 94.45% 100.00% 99.46% 97.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -389.46%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -360.04%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 311.86%
Return on Equity (ROE)		 -43.94% -15.46% -37.06% -69.13% -112.32% -77.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -33.22% -12.70% -19.56% -38.48% -64.38% -51.60%
Return on Assets (ROA)		 -29.39% -9.46% -20.53% -38.49% -64.03% -50.18%
Return on Common Equity (ROCE)		 -43.94% -15.46% -37.06% -69.13% -14.41% 154.58%
Return on Equity Simple (ROE_SIMPLE)		 -51.36% -13.50% -39.41% -44.83% -79.24% 38.95%
Net Operating Profit after Tax (NOPAT)		 -291 -124 -237 -275 -93 -53
NOPAT Margin		 -457.98% -32.71% -388.93% -529.91% -387,216.67% -292,265.56%
Net Nonoperating Expense Percent (NNEP)		 -8.41% -0.79% -5.10% -15.16% -52.52% -29.41%
Return On Investment Capital (ROIC_SIMPLE)		 -39.66% -12.59% -32.30% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 175.58% 30.93% 144.13% 110.37% 123,354.17% 114,183.33%
R&D to Revenue		 578.67% 115.80% 511.48% 746.64% 429,912.50% 303,438.89%
Operating Expenses to Revenue		 754.25% 146.73% 655.61% 857.01% 553,266.67% 417,622.22%
Earnings before Interest and Taxes (EBIT)		 -426 -178 -275 -371 -196 -81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -417 -178 -262 -363 -191 -78
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 2.80 2.26 3.76 6.57 19.27 0.00
Price to Tangible Book Value (P/TBV)		 2.80 2.26 3.76 6.57 19.27 0.00
Price to Revenue (P/Rev)		 32.33 5.87 45.24 104.73 197,180.98 10,000.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 29.21
Enterprise Value to Revenue (EV/Rev)		 18.94 2.72 27.54 86.11 184,694.69 21,922.89
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 74.48 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.04
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.04
Financial Leverage		 -1.19 -1.32 -1.31 -1.18 -1.12 -0.87
Leverage Ratio		 1.49 1.63 1.81 1.80 1.75 1.55
Compound Leverage Factor		 1.32 1.20 1.70 1.80 1.74 1.50
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.19%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 286.69%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -190.88%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.06
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.12
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.06
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.08
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 1.66
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.08
Altman Z-Score		 0.88 2.32 1.76 4.37 11.66 -1.06
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 87.17% 299.22%
Liquidity Ratios		 - - - - - -
Current Ratio		 4.82 5.89 4.89 5.96 3.01 3.24
Quick Ratio		 4.67 5.79 4.82 4.52 2.93 3.15
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -382 -260 -31 -190 -25 0.00
Operating Cash Flow to CapEx		 -3,881.58% -442.30% 46.02% -141.57% -585.32% -575.20%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -21,102.94 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -7,363.11 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -12,564.33 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.05 0.27 0.04 0.05 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.54 3.14 0.61 0.84 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -117 -209 -345 -139 -54 14
Invested Capital Turnover		 -0.39 -1.37 -0.25 -0.54 0.00 0.00
Increase / (Decrease) in Invested Capital		 91 136 -206 -85 -68 0.00
Enterprise Value (EV)		 1,203 1,029 1,678 4,464 4,433 395
Market Capitalization		 2,054 2,219 2,756 5,430 4,732 180
Book Value per Share		 $8.86 $12.04 $10.41 $12.13 $4.24 ($31.04)
Tangible Book Value per Share		 $8.86 $12.04 $10.41 $12.13 $4.24 ($31.04)
Total Capital		 734 981 733 827 246 105
Total Debt		 0.00 0.00 0.00 0.00 0.00 4.41
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 4.41
Net Debt		 -851 -1,190 -1,078 -966 -300 -87
Capital Expenditures (CapEx)		 8.95 34 49 47 16 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -155 -184 -209 94 -94 -26
Debt-free Net Working Capital (DFNWC)		 696 1,005 869 1,060 206 65
Net Working Capital (NWC)		 696 1,005 869 1,060 206 65
Net Nonoperating Expense (NNE)		 86 8.99 52 96 102 26
Net Nonoperating Obligations (NNO)		 -851 -1,190 -1,078 -966 -300 -87
Total Depreciation and Amortization (D&A)		 8.83 -0.21 13 7.38 4.85 2.58
Debt-free, Cash-free Net Working Capital to Revenue		 -243.49% -48.82% -342.80% 181.17% -390,362.50% -146,900.00%
Debt-free Net Working Capital to Revenue		 1,095.88% 266.20% 1,426.96% 2,043.77% 858,266.67% 363,366.67%
Net Working Capital to Revenue		 1,095.88% 266.20% 1,426.96% 2,043.77% 858,266.67% 363,366.67%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 ($4.58) ($1.72) ($4.13) ($5.77) ($4.19) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 82.31M 77.15M 70.02M 64.23M 62.42M 0.00
Adjusted Diluted Earnings per Share		 ($4.58) ($1.72) ($4.13) ($5.77) ($4.19) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 82.31M 77.15M 70.02M 64.23M 62.42M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($4.19) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 83.69M 81.66M 72.40M 68.73M 46.73M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -291 -124 -237 -275 -93 -53
Normalized NOPAT Margin		 -457.98% -32.71% -388.93% -529.91% -387,216.67% -292,265.56%
Pre Tax Income Margin		 -593.07% -34.73% -427.08% -714.91% -810,800.00% -435,144.44%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -41,181.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -30,525.06 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -46,382.22 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -35,726.28 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.48% -0.07% -2.38% -1.06% -3.22%

Quarterly Metrics And Ratios for Beam Therapeutics

This table displays calculated financial ratios and metrics derived from Beam Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.81% -90.49% -17.01% -41.48% -69.39% 1,478.04% 8.82% 20.80% 187.10% -60.76% 1,970.64%
EBITDA Growth		 -5.16% -165.04% 2.28% -8.27% -2.72% 470.48% -29.04% -36.74% -62.40% 39.38% -227.21%
EBIT Growth		 -7.77% -176.67% -0.01% -11.06% -3.85% 393.81% -25.55% -27.99% -52.34% 30.58% -208.06%
NOPAT Growth		 -14.55% -152.71% 1.63% -2.69% -5.26% 313.29% -18.58% -24.62% -29.78% -40.17% -31.12%
Net Income Growth		 -10.74% -163.27% -0.60% -10.00% -2.29% 472.36% 12.31% -15.05% -39.36% 40.73% -289.70%
EPS Growth		 -2.48% -157.07% 4.10% -2.78% 9.02% 453.70% 21.79% -5.88% -31.68% 29.87% -271.43%
Operating Cash Flow Growth		 -4.15% -156.54% 1.85% 1.96% 9.17% 295.22% -20.52% -61.97% -150.26% -3,880.93% -2,577.42%
Free Cash Flow Firm Growth		 11.62% -4,857.85% 19.48% -2.64% -15.15% -102.27% -203.45% -182.89% -163.61% 255.45% 298.29%
Invested Capital Growth		 46.53% 43.80% 43.16% 41.05% 39.23% 39.49% 37.77% 28.58% 24.28% -148.12% -265.01%
Revenue Q/Q Growth		 -75.16% 110.72% 21.21% 58.87% -97.66% 1,739.07% -14.53% -16.90% 20.82% 26.82% -5.12%
EBITDA Q/Q Growth		 -29.31% 16.64% -3.21% 5.47% -185.82% 225.24% -14.36% 10.32% -135.71% 56.38% -21.18%
EBIT Q/Q Growth		 -17.60% 6.91% -3.42% 4.81% -183.66% 221.43% -14.84% 10.99% -136.70% 48.11% -17.07%
NOPAT Q/Q Growth		 -19.24% 6.07% -1.53% -0.73% -154.86% 275.30% -5.99% -3.25% -11.17% 2.54% -11.39%
Net Income Q/Q Growth		 -20.94% 6.53% -6.17% 7.72% -169.10% 248.61% -16.08% 14.19% -151.53% 65.00% -52.29%
EPS Q/Q Growth		 -13.76% 6.84% -5.41% 8.26% -163.35% 256.56% -12.96% 18.80% -146.30% 65.38% -52.94%
Operating Cash Flow Q/Q Growth		 -36.04% 13.34% -6.16% 16.78% -173.85% 250.44% -6.04% 22.90% -58.71% 7.12% -42.51%
Free Cash Flow Firm Q/Q Growth		 -3.95% 8.63% 2.27% 4.78% -5,730.83% 98.52% -24.57% -6.84% -214.89% -32.34% -0.18%
Invested Capital Q/Q Growth		 17.39% 12.83% 12.74% 14.91% 13.18% 11.83% 9.51% 12.28% 13.55% 9.32% -3.86%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,571.99% -302.03% -763.49% -896.64% -1,506.92% 44.16% -648.42% -484.62% -449.05% -188.09% -546.81%
Operating Margin		 -1,596.87% -332.71% -746.40% -891.06% -1,405.29% 42.02% -629.72% -507.79% -408.66% -444.10% -577.90%
EBIT Margin		 -1,594.47% -336.85% -762.46% -893.66% -1,491.47% 41.78% -632.73% -470.91% -439.61% -224.38% -548.43%
Profit (Net Income) Margin		 -1,462.78% -300.51% -677.47% -773.45% -1,331.57% 45.16% -558.88% -411.49% -398.46% -191.39% -693.56%
Tax Burden Percent		 100.00% 47.80% 100.00% 100.04% 0.00% 299.35% 100.00% 100.00% 0.00% 102.68% 134.18%
Interest Burden Percent		 91.74% 186.63% 88.85% 86.51% 0.00% 36.11% 88.33% 87.38% 0.00% 83.07% 94.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -38.04% -43.94% -18.29% -17.17% -16.09% -15.46% -42.01% -40.60% -39.78% -37.06% -40.23%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -71.73% -16.69% -216.57% -240.96% -399.90% 11.27% -39.08% -27.23% -24.21% -9.71% -40.23%
Return on Assets (ROA)		 -65.80% -14.89% -192.43% -208.55% -357.02% 12.18% -34.52% -23.80% -21.94% -8.28% -50.88%
Return on Common Equity (ROCE)		 -38.04% -43.94% -18.29% -17.17% -16.09% -15.46% -42.01% -40.60% -39.78% -37.06% -40.23%
Return on Equity Simple (ROE_SIMPLE)		 -34.49% 0.00% -18.15% -16.74% -14.75% 0.00% -40.27% -40.31% -41.54% 0.00% -44.15%
Net Operating Profit after Tax (NOPAT)		 -84 -70 -75 -73 -73 133 -76 -72 -69 -62 -64
NOPAT Margin		 -1,117.81% -232.90% -522.48% -623.74% -983.70% 42.02% -440.80% -355.46% -286.06% -310.87% -404.53%
Net Nonoperating Expense Percent (NNEP)		 -2.23% -1.99% -2.28% -1.69% -2.39% 0.88% -1.92% -1.01% -2.38% 2.34% -4.45%
Return On Investment Capital (ROIC_SIMPLE)		 -7.43% -9.55% - - - 13.54% - - - -8.49% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 374.03% 95.32% 185.82% 251.67% 360.65% 13.68% 147.79% 122.57% 97.03% 113.20% 138.08%
R&D to Revenue		 1,322.84% 337.39% 660.58% 739.39% 1,144.64% 44.30% 581.92% 485.23% 411.62% 430.91% 539.83%
Operating Expenses to Revenue		 1,697.23% 432.71% 846.40% 991.06% 1,505.29% 57.98% 729.72% 607.79% 508.66% 544.10% 677.90%
Earnings before Interest and Taxes (EBIT)		 -119 -101 -109 -105 -111 132 -109 -95 -106 -45 -87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -117 -91 -109 -106 -112 140 -111 -97 -109 -38 -86
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.46 2.80 2.55 2.26 2.95 2.26 2.45 3.00 2.91 3.76 4.69
Price to Tangible Book Value (P/TBV)		 1.46 2.80 2.55 2.26 2.95 2.26 2.45 3.00 2.91 3.76 4.69
Price to Revenue (P/Rev)		 25.71 32.33 5.78 5.47 7.46 5.87 23.36 30.36 28.90 45.24 36.45
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 6.52 18.94 3.13 2.61 4.43 2.72 10.90 16.97 15.09 27.54 24.55
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 74.48 24.13
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 39.69
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.19 -1.24 -1.25 -1.29 -1.32 -1.41 -1.39 -1.43 -1.31 -1.31
Leverage Ratio		 1.39 1.49 1.57 1.57 1.61 1.63 1.77 1.72 1.75 1.81 1.60
Compound Leverage Factor		 1.27 2.79 1.39 1.36 0.00 0.59 1.56 1.50 0.00 1.50 1.51
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.93 1.85 2.21 2.13 3.12 3.03 1.33 2.03 1.69 2.33 2.74
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.81 4.82 5.69 5.81 5.99 5.89 4.72 5.22 4.92 4.89 4.64
Quick Ratio		 8.62 4.67 5.57 5.69 5.85 5.79 4.61 5.12 4.82 4.82 4.58
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -168 -161 -177 -181 -190 -3.26 -219 -176 -165 143 212
Operating Cash Flow to CapEx		 -3,389.36% -2,571.21% -5,588.14% -4,232.99% -4,091.35% 3,763.53% -1,129.64% -523.36% -1,825.08% -837.56% -632.02%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.05 0.28 0.27 0.27 0.27 0.06 0.06 0.06 0.04 0.07
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.55 0.54 2.90 2.87 2.97 3.14 0.68 0.68 0.71 0.61 1.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -97 -117 -134 -154 -181 -209 -237 -261 -298 -345 -380
Invested Capital Turnover		 -0.46 -0.39 -1.89 -1.70 -1.51 -1.37 -0.26 -0.26 -0.22 -0.25 -0.38
Increase / (Decrease) in Invested Capital		 84 91 102 107 117 136 144 105 96 -206 -276
Enterprise Value (EV)		 414 1,203 1,093 920 1,598 1,029 889 1,361 1,157 1,678 2,257
Market Capitalization		 1,634 2,054 2,019 1,929 2,693 2,219 1,905 2,434 2,217 2,756 3,352
Book Value per Share		 $13.42 $8.86 $9.60 $10.38 $11.18 $12.04 $9.84 $10.65 $10.52 $10.41 $10.16
Tangible Book Value per Share		 $13.42 $8.86 $9.60 $10.38 $11.18 $12.04 $9.84 $10.65 $10.52 $10.41 $10.16
Total Capital		 1,123 734 791 854 913 981 779 812 762 733 714
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,220 -851 -926 -1,008 -1,095 -1,190 -1,015 -1,073 -1,059 -1,078 -1,095
Capital Expenditures (CapEx)		 3.07 2.97 1.58 1.96 2.44 3.59 7.95 16 6.02 8.26 12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -114 -155 -146 -156 -160 -184 -196 -188 -196 -209 -225
Debt-free Net Working Capital (DFNWC)		 1,106 696 779 852 934 1,005 819 885 863 869 870
Net Working Capital (NWC)		 1,106 696 779 852 934 1,005 819 885 863 869 870
Net Nonoperating Expense (NNE)		 26 20 22 18 26 -9.94 20 11 27 -24 46
Net Nonoperating Obligations (NNO)		 -1,220 -851 -926 -1,008 -1,095 -1,190 -1,015 -1,073 -1,059 -1,078 -1,095
Total Depreciation and Amortization (D&A)		 1.68 10 -0.15 -0.35 -1.15 7.53 -2.70 -2.76 -2.29 7.27 0.26
Debt-free, Cash-free Net Working Capital to Revenue		 -179.12% -243.49% -41.89% -44.26% -44.35% -48.82% -240.68% -234.22% -256.03% -342.80% -244.15%
Debt-free Net Working Capital to Revenue		 1,739.70% 1,095.88% 222.88% 241.69% 258.93% 266.20% 1,004.46% 1,104.38% 1,125.36% 1,426.96% 946.20%
Net Working Capital to Revenue		 1,739.70% 1,095.88% 222.88% 241.69% 258.93% 266.20% 1,004.46% 1,104.38% 1,125.36% 1,426.96% 946.20%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.24) ($1.09) ($1.17) ($1.11) ($1.21) $1.91 ($1.22) ($1.08) ($1.33) ($0.54) ($1.56)
Adjusted Weighted Average Basic Shares Outstanding		 87.98M 82.31M 82.41M 82.31M 81.70M 77.15M 79.02M 76.34M 72.27M 70.02M 70.34M
Adjusted Diluted Earnings per Share		 ($1.24) ($1.09) ($1.17) ($1.11) ($1.21) $1.91 ($1.22) ($1.08) ($1.33) ($0.54) ($1.56)
Adjusted Weighted Average Diluted Shares Outstanding		 87.98M 82.31M 82.41M 82.31M 81.70M 77.15M 79.02M 76.34M 72.27M 70.02M 70.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 100.56M 83.69M 82.81M 82.42M 82.31M 81.66M 81.50M 79.20M 76.22M 72.40M 70.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -83 -70 -75 -73 -73 93 -76 -72 -69 -62 -64
Normalized NOPAT Margin		 -1,117.55% -232.90% -522.48% -623.74% -983.70% 29.41% -440.80% -355.46% -286.06% -310.87% -404.53%
Pre Tax Income Margin		 -1,462.78% -628.67% -677.47% -773.12% 0.00% 15.09% -558.88% -411.49% 0.00% -186.40% -516.90%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.27% -0.42% -0.48% -0.22% -0.10% -0.08% -0.07% -0.08%

Frequently Asked Questions About Beam Therapeutics' Financials

When does Beam Therapeutics's financial year end?

According to the most recent income statement we have on file, Beam Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Beam Therapeutics' net income changed over the last 5 years?

Beam Therapeutics' net income appears to be on an upward trend, with a most recent value of -$376.74 million in 2024, rising from -$78.33 million in 2019. The previous period was -$132.53 million in 2023. Check out Beam Therapeutics' forecast to explore projected trends and price targets.

What is Beam Therapeutics's operating income?
Beam Therapeutics's total operating income in 2024 was -$415.57 million, based on the following breakdown:
  • Total Gross Profit: $63.52 million
  • Total Operating Expenses: $479.09 million
How has Beam Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Beam Therapeutics' total revenue changed from $18 thousand in 2019 to $63.52 million in 2024, a change of 352,777.8%.

How much debt does Beam Therapeutics have?

Beam Therapeutics' total liabilities were at $370.28 million at the end of 2024, a 22.6% decrease from 2023, and a 571.4% increase since 2019.

How much cash does Beam Therapeutics have?

In the past 5 years, Beam Therapeutics' cash and equivalents has ranged from $37.22 million in 2019 to $559.99 million in 2021, and is currently $281.97 million as of their latest financial filing in 2024.

How has Beam Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Beam Therapeutics' book value per share changed from -31.04 in 2019 to 8.86 in 2024, a change of -128.5%.


Related Companies

This page (NASDAQ:BEAM) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...
Weiss Ratings | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored